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ABSTRACT. Crohn’s disease is a chronic, relapsing inflammatory 
bowel disease; it affects the mucosa and deeper layers of the digestive 
wall. Two Crohn’s disease patients who carried the JW1 variant and 
two patients who carried the SNP5 variant were investigated for other 
co-inherited polymorphisms that could influence Crohn’s disease de-
velopment. Based on the sequencing results, a homozygous 5ꞌ-UTR-59 
G to A variant in exon 1 (SNP6) was observed in a patient who carried 
SNP5, while a heterozygous SNP6 variant was detected in the other 
patient who carried SNP5. No other associated mutations or polymor-
phisms were detected in the two patients who carried the JW1 variant 
of the CARD15/NOD2 gene. 
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INTRODUCTION
Crohn’s disease (CD) is a major form of chronic inflammatory bowel disease, apart 
from ulcerative colitis (Sugimura et al., 2003). CD usually causes swelling in the intestines, 
and can affect any part of the gastrointestinal tract, although it tends to affect the terminal ileum 
and proximal colon (Russell et al., 2004). In CD, all layers of the intestine can be affected and 
normal healthy bowel can be found between the sections of diseased bowel (Podolsky, 1991a). 
Clinical manifestations of CD are variable among individuals in the same population. Its 
inflammatory process is more complex than other inflammatory bowel diseases. The main feature 
that distinguishes it from other inflammatory bowel diseases is the extension of the infiltrate into 
the deeper layers of the bowel wall (Podolsky, 1991b). This process can lead to fistulizing compli-
cations after a long period of infection, since the inflammation is transmural (Russell et al., 2004). 
CD commonly develops in the teenage years or between the ages of 20 to 30, but indi-
viduals aged above 60 years also have the tendency to develop this disease, which can affect their 
life quality. However, phenotypes, genetics, and environmental influences are different between 
younger and older individuals (Polito et al., 1996). Polito et al. (1996) also found that younger pa-
tients usually have a more severe manifestation of CD compared to older patients. Therefore, they 
usually experience a more complicated disease course and surgery is typically required to cure the 
disease. Furthermore, patients who are diagnosed at early ages (especially those diagnosed before 
they reach 20 years of age) are often associated with positive family history (Polito et al., 1996).
In general, CD is more common in northern countries (Shivananda et al., 1996). Pre-
vious population studies in Norway and the United States showed that the incidence of CD 
in these 2 countries is similar, which is approximately 6 to 7.1:100,000 (Moum et al., 1996). 
Russell et al. (2004) reported that CD affects about 1 in 250 individuals in northern European 
populations. In addition, the frequency of CD is also very high among the Ashkenazi Jew 
population (Podolsky, 2002). On the other hand, the incidence of CD is very low in Asia and 
Africa. Although the exact cause of CD is unknown, both genetic and environmental factors 
are believed to be the major causes of this disease (Chua et al., 2011a, 2012).
Genetic factors are the important factors that contribute to the development of CD. At 
least 1/6 of CD patients have positive family history (Polito et al., 1996). In addition, the risk 
of CD is increased by approximately 5 to 10% among first-degree relatives of affected patients 
(Bennett et al., 1991; Podolsky, 1991a). In addition, studies also show that the risk of developing 
CD increases 30 times when an individual has a sibling with CD (Fielding, 1986). Moreover, 
studies in monozygotic twins also show that the rate of CD is very high among them, at approxi-
mately 55% (Tysk et al., 1988). However, genetic factors are less of influence in older patients 
(Polito et al., 1996). In a previous report, Ogura et al. (2001) found that mutations in the caspase 
recruitment domain-containing protein 15/nucleotide-binding oligomerization domain-contain-
ing protein 2 (CARD15/NOD2) gene are associated with CD. In this study, we aimed to study the 
co-inheritance of single nucleotide polymorphisms (SNPs) with SNP5 or JW1 in our Malaysian 
patients, as these variations may have the potential to mediate CD development.
MATERIAL AND METHODS
Patient sample
Four CD patients who were identified as carrying the SNP5 (patients labeled as CD17 
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and CD51) or JW1 (patients labeled as CD47 and CD49) mutation in a previous research study 
were included in the present study (Chua et al., 2009). The samples were obtained with informed 
consent from the University of Malaya Medical Center (Ethics Approval No. 472.55). Ethnic 
group, age, gender, and type of mutation for the 4 patients were recorded. Phenotype, location, and 
behavior of the disease in each of the patients were also classified and recorded.
DNA extraction from blood and primer design
DNA was extracted from blood using a simplified conventional method as stated previ-
ously (Tan et al., 2010).
For the primer design, the sequence of the CARD15/NOD2 gene was obtained from the 
National Center for Biotechnology Information (NCBI) website (GeneID: 64127). The total length 
of CARD15/NOD2 gene is approximately 35 kbp (GenBank accession No. NT_010498), which 
are composed of 12 exons; the length of its encoding mRNA is 4485 bp (GenBank accession No. 
NM_022162). 
Twelve pairs of primers designed to cover all the studied regions (including intron-exon 
boundaries) were designed using the Primer 3 software (http://frodo.wi.mit.edu). Primer specificity 
checks using a similar in silico polymerase chain reaction (PCR) approach as reported previously 
were also carried out to ensure that the newly designed primers were targeted to the specific DNA 
regions of interest (Chua et al., 2011b; Thong et al., 2011; Ng et al., 2012a,b). The primer sequences 
are shown in Table 1. The JW1, SNP5, R702W, and G908R mutations had been studied in our previ-
ous report (Chua et al., 2009); therefore, these particular regions were excluded in the present study. 
PCR amplification and electrophoresis
PCR in this study was performed with the primers that are listed in Table 1. The PCR mix 
was composed of 2.5 mL 1X reaction buffer, 1.25 mL 5% DMSO, 0.5 mL 0.2 mM dNTP, 5 mL 0.5 
mM forward primer, 5 mL 0.5 mM reverse primer, 0.4 mL Taq DNA polymerase (Promega, USA), 
50 ng DNA sample and an appropriate amount of distilled water. A few standard programs with 
slight modifications as reported previously have been used to carry out all the PCR amplifications 
in this study (Puah et al., 2007; Teh et al., 2010; Chan et al., 2011). The PCR products were then 
electrophoresed on 1.5% (w/v) agarose gels and viewed under a UV transilluminator. 
DNA purification and sequencing
The DNA was purified from the PCR product using the AccuPrep PCR purification kit 
(Bioneer Life Science Corporation, Korea), according to manufacturer instructions. Following pu-
rification, the DNA was sent to Medigene (Malaysia) for direct sequencing. Finally, the sequencing 
results were analyzed using Chromas 2.33 (http://www.technelysium.com.au/chromas.html) and 
ClustalX (http://www.clustal.org) softwares.
RESULTS
Genomic DNA was successfully extracted from the patient samples, and the PCR products 
and sequencing results were also successfully obtained in this study. The overall sequencing results 
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showed that a nucleotide substitution was observed at position nt. 1482, exon 4 in sample CD51 
(thymine and cytosine) while the reverse strand had normal sequences (adenine and guanine) at 
the same position without any observed nucleotide mutation/substation (Figure 1). On the other 
hand, Figure 2 shows that the patient labeled as CD17 had a single base pair substitution (nt. 47) at 
the 5ꞌ-untranslated region (UTR) of exon 1. Adenine was observed in the 5ꞌ-UTR of exon 1 in the 
forward strand, while thymine was observed in the reverse strand.
Exon Primer Nucleotide sequence
  1 F: intron  5ꞌ-GAAGGTGGGGTTGGTAGACA-3ꞌ
 R: intron 5ꞌ-CCAGAAAACAGCCCAGAAAC-3ꞌ
  2 F: intron 5ꞌ-CTCGGGTTCTGCTGGGGCT-3ꞌ
 R: intron 5ꞌ-GTGACTAAGCACCCCTTTCC-3ꞌ
  3 F: intron 5ꞌ-ACATTGCTCCATCAGCCTTCC-3ꞌ
 R: intron 5ꞌ-GACTGCCCTTCCCTTTCTG-3ꞌ
  4(a) F: exon 5ꞌ-TTGTCTTCCCATTCAGCTGCC-3ꞌ
 R: exon 5ꞌ-TCAGGTACAGCTCGATGCCC-3ꞌ
  4(b) F: exon 5ꞌ-GAAGTACATCCGCACCGAG-3ꞌ
 R: exon 5ꞌ-AGGTAGAACGCGGCAAAGAA-3ꞌ
  4(c) F: exon 5ꞌ-GAATTCCTTCACATCACTTTCCAGT-3ꞌ
 R: intron 5ꞌ-ACTTAGCCTTGATGGTGCTC-3ꞌ
  5+6 F: intron 5ꞌ-TCCATCTATGCAGGGTTTCCTG-3ꞌ
 R: intron 5ꞌ-GGGAGATCACAGCATTAGAGAA-3ꞌ
  7 F: intron 5ꞌ-CTGCCTGCCGCTGTGTTCTC-3ꞌ
 R: intron 5ꞌ-CCTAAATCCTCAAAAGTCCCAA-3ꞌ
  9 F: intron 5ꞌ-GGTCTTTCCCTGCTCTGACA-3ꞌ
 R: intron 5ꞌ-GGGATCAACAGAGATTGTGA-3ꞌ
10 F: exon 5ꞌ-TGGAGGAGAACCATCTCCAG-3ꞌ
 R: intron 5ꞌ-GGAGAGCGGCCCAGATCTTA-3ꞌ
11 F: intron 5ꞌ-CTCACCATTGTATCTTCTTTTC-3ꞌ
 R: intron 5ꞌ-CCTCAAAATTCTGCCATTCC-3ꞌ
12 F: intron 5ꞌ-TGGGTTTAAAAAGTGGAGGC-3ꞌ
 R: intron 5ꞌ-CAAACTCACAGCCTGCTCAC-3ꞌ
Table 1. Primers used in this study.
Figure 1. Partial DNA sequence of exon 4 of sample CD51.
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DISCUSSION
Although the exact etiology of CD remains unknown even after numerous clinical and 
experimental studies have been conducted, environmental factors and genetic predisposition 
are confirmed to be the major factors that cause CD. In addition, a previous report revealed 
that the etiology of CD is associated with a dysregulated immune response to microbial or-
ganisms in the gastrointestinal tract, which subsequently leads to inflammatory cell damage 
(Vermeire et al., 2002). 
In terms of genetic factors, CARD15/NOD2, a gene located at the pericentromemic re-
gion on chromosome 16, confers susceptibility to CD (Hugot et al., 2001; Ogura et al., 2001). 
The CARD15/NOD2 protein functions as a sensor for bacterial lipopolysaccharide through a 
leucine-rich repeat domain, which results in the activation of the nuclear factor-kB (NF-kB) 
pathway and in apoptosis under normal conditions (Vermeire et al., 2002).
Three main disease-causing mutations, R702W (exon 4, labeled as SNP8), G908R 
(exon 8, labeled as SNP12), and 1007 frame shift (exon 11, labeled as SNP13) were identi-
fied by Hugot et al. (2001). In our previous molecular study involving these 3 disease-causing 
mutations, none of our Malaysian patients with CD carried any of these mutations (Chua et 
al., 2009). This is likely due to genetic heterogeneity with regard to the causative factors for 
CD between Caucasian and Asian populations. On the other hand, the other 2 variants, SNP5 
(exon 4) and JW1 (exon 8), were detected in our patients with CD. These 2 variants are com-
monly found in Jewish populations (Sugimura et al., 2003) and have been reported to confer 
susceptibility to CD in combination with other variants. 
In this study, further investigation through sequencing was performed for the 4 se-
lected patients to determine whether there is any additional disease-predisposing mutation or 
Figure 2. Partial DNA sequence of 5ꞌ-UTR in exon 1 of sample CD17.
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variant in the CARD15/NOD2 gene that acts in combination of SNP5 or JW1 to result in a 
more serious pathologic CD manifestation.
The DNA sequence chromatogram (Figure 1) shows that sample CD51 is a hetero-
zygote variant with a single base pair substitution at nucleotide 1482 (with a base changes 
from C (wild type) to T (variant)) in exon 4. SNP6 (rs2066834) is a synonymous variant, as it 
has no changes in amino acids; the amino acid it codes for, arginine, remains the same in this 
case. R459R (also known as SNP6 by Hugot et al. (2001)) is located at the nucleotide binding 
domain of the CARD15/NOD2 gene. The SNP6 variant, a silent mutation, was found to be in 
linkage disequilibrium with the 3 main mutations (R702W, G908R, and 1007fs) (Lesage et al., 
2002). Of note, some studies reported that the SNP6 variant could be found in both Caucasian 
and Jewish populations (Lesage et al., 2002; Sugimura et al., 2003). 
According to the sequencing results shown in Figure 2, the substitution of G to A was 
observed in sample CD17; this observation indicates that this is a homozygote variant. The 
variant is located at nucleotide 59 from the transcription start site in the 5ꞌ-UTR of exon 1. 
The 5ꞌUTR-59 (rs2076752) is considered to be a SNP and was also reported to exist among 
other populations, including those from Quebec (Vermeire et al., 2002) and Jewish popula-
tions (Sugimura et al., 2003). 
There are approximately 65 variants in the CARD15/NOD2 gene (including the 1007fs 
frameshift mutation) that are usually found to be associated with CD in Western populations; 
however, these were absent in our 4 patients in this study (Lesage et al., 2002; Sugimura et al., 
2003; Vermeire et al., 2004). No additional mutation or polymorphism, with the exceptions of 
SNP6 and 5ꞌUTR-59, was observed from exon 1 to 12 (including intron-exon boundaries) in 
the CARD15/NOD2 gene of these patients.
In conclusion, patient CD17 had a SNP5 variant and a 5ꞌUTR-59 G to A substitution, 
while patient CD51 had SNP5 and SNP6 variants. No other mutation or polymorphism was 
detected in the 2 patients who carried the JW1 CARD15/NOD2 gene variant. Overall, the co-
inheritance of SNPs has the potential to influence disease severity. However, this study dem-
onstrated that Malaysian patients with CD do not exhibit a similar pattern of co-inheritance of 
disease-predisposing SNPs. 
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